2. Overview of studies conducted in areas of moderate endemicity.

Study ID	Design	Country	Year	Endemicity	MDA group						Control group/baseline
					Drug (dose)	Interval	No. of rounds	Population targeted	Coverage	Co‐intervention
Najera 1973	N‐RCS	Nigeria	1966‐68	29%*	CQ (450 mg) + Pyr (45 mg)	2 months	11	52,000	78‐92%	IRS	IRS alone
Singh 1953	N‐RCS	India	1952‐53	22%*	AQ (600 mg)	2 weeks	5	125	ND	None	No intervention
Jones 1958	N‐RCS	Kenya	1952‐53	34%†	Pyr (100 mg)	6 months	3	3721‐4500	ND	None	No intervention
Roberts 1964	N‐RCS	Kenya	1953	28%*	Pyr (50 mg)	‐	1	101,000	95%	None	No intervention
	N‐RCS	Kenya	1954	22%*	Pyr (50 mg)	‐	1	99,000	95%	None	No intervention
Archibald 1960	BAS	Nigeria	1958	29%†	CQ (600 mg) + Pyr (25 mg)	1 month	5	10,000	ND	IRS	IRS
Cavalie 1962	BAS	Cameroon	1960‐61	20%†	CQ (600 mg) + Pyr (50 mg)	4 months	2	22,500	76‐92%	IRS	IRS
Houel 1954	BAS	Morocco	1953	14%†	Pyr (100 mg)	‐	1	9999	ND	IRS	IRS
Metselaar 1961	BAS	New Guinea	1958‐59	13‐21%†	CQ (450 mg) +Pyr (50 mg)	1 week	6	2500	90%	IRS	IRS
Jones 1954	BAS	Kenya	1952‐53	35%†	Pyr (100 mg)	6 months	3	3721	ND	None	‐
van Dijk 1961	BAS	Papua New Guinea	1960	39%†	CQ (450 mg)	4 weeks	11	1250	97%	None	‐
Comer 1971	BAS	Panama	1965‐68	17%*	Pyr (50 mg / 75 mg) + PQ (40 mg)	2 weeks	49	1709	61‐87%	None	‐

N‐RCS = Non‐randomized controlled study; BAS = Uncontrolled before‐and‐after study; AQ = Amodiaquine; Pyr = Pyrimethamine; CQ = Chloroquine; PQ = Primaquine; ND = Not described; IRS = Indoor Residual Spraying.

*In all ages

†Amongst children only